Kenza Health Hub logoGet Started

Table of contents

Therapeutic actionIndicationsForms and strengthsDose and durationContra-indications, adverse effects, precautions
1 May 2026Oral drugs

Artesunate/Amodiaquine Oral: Malaria Dosing Guide

Artesunate/amodiaquine guidance for uncomplicated malaria and completion treatment after severe malaria, with once-daily dosing for 3 days.

Also searched as

AS/AQ oralArtesunate/amodiaquine
Prescription under medical supervision

Source reviewed

source date listed on the source page

Guide category

Oral drugs

Safety boundary

Prescription medicine information for clinician-guided use.

Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.

This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Antimalarial.

Indications

  • Treatment of uncomplicated falciparum malaria.
  • Treatment of uncomplicated malaria due to other Plasmodium species, when chloroquine cannot be used.
  • Completion treatment following parenteral therapy for severe malaria.

Forms and strengths

Co-formulated tablets of artesunate and amodiaquine in blister packs for a complete treatment for one individual.

There are 4 different blister packs corresponding to 4 different categories of weight.

  • 25 mg artesunate/67.5 mg amodiaquine base tablet, blister pack of 3 tablets.
  • 50 mg artesunate/135 mg amodiaquine base tablet, blister pack of 3 tablets.
  • 100 mg artesunate/270 mg amodiaquine base tablet, blister pack of 3 tablets.
  • 100 mg artesunate/270 mg amodiaquine base tablet, blister pack of 6 tablets.

Dose and duration

Tablets are to be taken once daily for 3 days.

Artesunate/amodiaquine dosing by weight and treatment day
WeightTabletsD1D2D3
4.5 to < 9 kg25 mg AS/67.5 mg AQ base1 tab1 tab1 tab
9 to < 18 kg50 mg AS/135 mg AQ base1 tab1 tab1 tab
18 to < 36 kg100 mg AS/270 mg AQ base blister pack of 3 tab1 tab1 tab1 tab
≥ 36 kg100 mg AS/270 mg AQ base blister pack of 6 tab2 tab2 tab2 tab

Weight-based dosing

  • 4.5 to < 9 kg: 25 mg AS/67.5 mg AQ base, 1 tablet on D1, D2, and D3.
  • 9 to < 18 kg: 50 mg AS/135 mg AQ base, 1 tablet on D1, D2, and D3.
  • 18 to < 36 kg: 100 mg AS/270 mg AQ base, blister pack of 3 tablets, 1 tablet on D1, D2, and D3.
  • >= 36 kg: 100 mg AS/270 mg AQ base, blister pack of 6 tablets, 2 tablets on D1, D2, and D3.

Contra-indications, adverse effects, precautions

  • Do not administer in the event of previous severe adverse reaction to treatment with amodiaquine, such as hypersensitivity reaction, hepatitis, leucopenia, or agranulocytosis.
  • Do not administer to patients taking efavirenz.
  • Avoid combination with drugs that prolong the QT interval, including amiodarone, other antimalarials, antipsychotics, fluconazole, fluoroquinolones, hydroxyzine, macrolides, and ondansetron.
  • May cause gastrointestinal disturbances, pruritus, somnolence or insomnia, and cough.
  • If the patient vomits within 30 minutes after administration, re-administer the full dose.
  • If the patient vomits between 30 minutes and 1 hour after administration, re-administer half of the dose.
  • Pregnancy: no contra-indication.
  • Breast-feeding: no contra-indication.

Source

MSF Essential drugs practical guidelines (January 2026)

This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.

Rate this guide

Be the first to rate this guide.